ArticleCancer cell2015
Erythropoietin Stimulates Tumor Growth via EphB4.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 96 citations in OpenAlex.
- First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.British journal of clinical pharmacology · 2018Trial
- Erythropoietin in Tumor Immunity: Mechanistic Evidence, Clinical Cautions, and Translational Opportunities.Cancers · 2026Review
- Forebrain-specific loss of erythropoietin provokes compensatory upregulation of different EPO receptors.Molecular psychiatry · 2026Article
- Tetravalent antibodies are more potent and efficacious erythropoiesis-stimulating agents than erythropoietin in vivo.Protein science : a publication of the Protein Society · 2026Article
- Erythropoietin in tissue engineering and beyond: a multifunctional macromolecule with emerging roles in organoids, immune modulation, and cancer research.Frontiers in bioengineering and biotechnology · 2026Review
- Erythropoietin promotes cell proliferation in Neuro-2A mouse neuroblastoma cells.Biochemistry and biophysics reports · 2025Article
- An asymmetric tetrabody is a potent and efficacious agonist of the erythropoietin receptor in vitro and in vivo.Protein science : a publication of the Protein Society · 2025Article
- Mechanisms and Management of Albumin-Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer.Breast cancer (Dove Medical Press) · 2025Review
- Effect of recombinant human erythropoietin on postoperative anemia in children and adolescents undergoing osteosarcoma and potential influencing factors: a single-center retrospective study.Frontiers in pharmacology · 2025Article
- Pre-treatment anemia in head and neck cancer: risk factors, subtypes, and survival outcomes.Frontiers in oncology · 2025Article
- Lipoprotein metabolism mediates hematopoietic stem cell responses under acute anemic conditions.Nature communications · 2024Article
- An investigation of binding interactions of tumor-targeted peptide conjugated polyphenols with the kinase domain of ephrin B4 and B2 receptors.Molecular diversity · 2024Article
- Eph receptors and ephrins in cancer progression.Nature reviews. Cancer · 2024Review
- Mechanisms of Postischemic Stroke Angiogenesis: A Multifaceted Approach.Journal of inflammation research · 2024Review
- Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches.Frontiers in oncology · 2024Review
- Aberrant epithelial cell interaction promotes esophageal squamous-cell carcinoma development and progression.Signal transduction and targeted therapy · 2023Article
- Erythroid Cells as Full Participants in the Tumor Microenvironment.International journal of molecular sciences · 2023Review
- Heterogeneity in leukemia cells that escape drug-induced senescence-like state.Cell death & disease · 2023Article
- Tumor-associated myeloid cells in cancer immunotherapy.Journal of hematology & oncology · 2023Review
- Synergistic immunotherapy targeting cancer-associated anemia: prospects of a combination strategy.Cell communication and signaling : CCS · 2023Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors at 5 institutions in 4 countries.
Sunila PradeepDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Jie HuangDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Edna M MoraDepartment of Surgery, University of Puerto Rico, San Juan 00936, Puerto Rico; University of Puerto Rico Comprehensive Cancer Center, San Juan 00936, Puerto Rico; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Alpa M NickDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Min Soon ChoDepartment of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Sherry Y WuDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Kyunghee NohDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Chad V PecotDivision of Hematology/Oncology, University of North Carolina, Chapel Hill, NC 27599, USA.
Rajesha RupaimooleDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Martin A SteinMolecular Health, GmbH, Heidelberg 69115, Germany.
Stephan BrockMolecular Health, GmbH, Heidelberg 69115, Germany.
Yunfei WenDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Chiyi XiongDepartment of Experimental Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Kshipra GharpureDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Jean M HansenDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Archana S NagarajaDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Rebecca A PrevisDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Pablo Vivas-MejiaDepartment of Surgery, University of Puerto Rico, San Juan 00936, Puerto Rico.
Hee Dong HanDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA; Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Wei HuDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Lingegowda S MangalaDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA; Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Behrouz ZandDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Loren J StaggDepartment of Biochemistry and Molecular Biology and Center for Biomolecular Structure and Function, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
John E LadburyDepartment of Biochemistry and Molecular Biology and Center for Biomolecular Structure and Function, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Bulent OzpolatDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
S Neslihan AlpayDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Masato NishimuraDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Rebecca L StoneDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Koji MatsuoDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Guillermo N Armaiz-PeñaDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Heather J DaltonDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Christopher DanesDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Blake GoodmanDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Cristian Rodriguez-AguayoDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Carola KrugerMolecular Neurology, Sygnis AG, Heidelberg 69120, Germany.
Armin SchneiderMolecular Neurology, Sygnis AG, Heidelberg 69120, Germany.
Shyon HaghpeykarDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Padmavathi JaladurgamDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Mien-Chie HungMolecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University, Taichung 402, Taiwan.
Robert L ColemanDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Jinsong LiuDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Chun LiDepartment of Biochemistry and Molecular Biology and Center for Biomolecular Structure and Function, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Diana UrbauerBiostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Gabriel Lopez-BeresteinCenter for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
David B JacksonMolecular Health, GmbH, Heidelberg 69115, Germany.
Anil K SoodDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA; Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: asood@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USExpedeon (Germany) · DEUniversity of Puerto Rico System · PRChina Medical University · TWUniversity of North Carolina at Chapel Hill · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0MTargeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0MUPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Larkin Strong · 2002 to 2026
$23.8MTexas Center for Cancer NanomedicineU54CA151668 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2010 to 2014
$12.4MTraining of Academic Gynecologic OncologistsT32CA101642 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIL K SOOD, Kathleen Schmeler · 2005 to 2026
$9.2MOvarian Cancer: Mechanisms of Neuroendocrine RegulationR01CA109298 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2005 to 2017
$4.5MPlatelets promote growth of ovarian cancerR01CA177909 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AFSHAR-KHARGHAN, VAHID, SOOD, ANIL K · 2013 to 2023
$4.1MNovel extra cellular RNA-based combinatorial RNA inhibition therapyUH3TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2015 to 2017
$3.2MBaylor WRHR ProgramK12HD050128 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI BROWN, DALE · 2005 to 2009
$1.8MNanovectors for Characterization and Destruction of Breast Tumor VasculatureR01CA128797 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2007 to 2010
$1.7MNovel extra cellular RNA-based combinatorial RNA inhibition therapyUH2TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2013 to 2014
$1.1MNCATS NIH HHS UH2 TR000943NCATS NIH HHS UH3 TR000943NCI NIH HHS CA 109298NCI NIH HHS CA 16672NCI NIH HHS CA 177909NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA098258NCI NIH HHS R01 CA109298NCI NIH HHS R01 CA128797NCI NIH HHS R01 CA177909NCI NIH HHS T32 CA101642NCI NIH HHS U54 CA 096300NCI NIH HHS U54 CA096300NCI NIH HHS U54 CA151668NCI NIH HHS U54CA151668NICHD NIH HHS K12 HD050128
Abstract
While recombinant human erythropoietin (rhEpo) has been widely used to treat anemia in cancer patients, concerns about its adverse effects on patient survival have emerged. A lack of correlation between expression of the canonical EpoR and rhEpo's effects on cancer cells prompted us to consider the existence of an alternative Epo receptor. Here, we identified EphB4 as an Epo receptor that triggers downstream signaling via STAT3 and promotes rhEpo-induced tumor growth and progression. In human ovarian and breast cancer samples, expression of EphB4 rather than the canonical EpoR correlated with decreased disease-specific survival in rhEpo-treated patients. These results identify EphB4 as a critical mediator of erythropoietin-induced tumor progression and further provide clinically significant dimension to the biology of erythropoietin.
Indexed as
AdultAgedAged, 80 and overAnimalsBlotting, WesternBreast NeoplasmsCell Line, TumorDisease ProgressionErythropoietinFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMCF-7 CellsMice, Inbred C57BLMice, NudeErythropoietinReceptor, EphB4Receptors, ErythropoietinRecombinant ProteinsSTAT3 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.